Seventh Sense Biosystems Inc. Receives $3.28 Million Grand Challenges Point-of-Care Diagnostics Grant to Expand Touch Activated Phlebotomy™ Technology Platform
Published: Dec 16, 2011
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seventh Sense Biosystems, Inc., a company developing novel blood sampling technology for decentralized diagnostic testing, announced today that it has been awarded a $3.28 million grant from the Bill & Melinda Gates Foundation. The grant is part of the Grand Challenges in Global Health initiative to seek out innovative ideas for diagnostics in the developing world. Seventh Sense’s proprietary Touch Activated Phlebotomy™ (TAP) technology platform is one of more than twenty Grand Challenges point-of-care diagnostics grants announced today. This Grand Challenges program aims to create technologies and components that can enhance assessment of conditions and pathogens at the point-of-care in a variety of settings.